All lobbying filings

GRIFOLS SHARED SERVICES NORTH AMERICA, INC.

Lobbying for GRIFOLS SHARED SERVICES NORTH AMERICA INC

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $470,000.00 expenses · posted Jan 18, 2026

Official filing document

Bills named in this filing 9

HR 1476
PLASMA Act
S 694
PLASMA Act
HR 1143
Medicare IVIG Access Enhancement Act of 2025
HR 2343
John W. Walsh Alpha-1 Home Infusion Act of 2025
S 1818
Prescription Drug Price Relief Act of 2025
HR 3546
Prescription Drug Price Relief Act of 2025
S 1587
Fair Prescription Drug Prices for Americans Act
HR 3375
Fair Prescription Drug Prices for Americans Act
S 1753
End Price Gouging for Medications Act

Lobbying activity 4

Health Issues

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

Immigration

Issues related to immigration policy

Budget/Appropriations

FY2026 Appropriations bill for Labor, Health and Human Services

Tariff (miscellaneous tariff bills)

Issues related to tariff policy; tariffs on pharmaceuticals and related products

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.